Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.

• Background: This pilot study evaluated the acute effects of topical ocular apraclonidine 1% (Iopidine) in 10 patients with presumed silicone oil-induced secondary glaucoma (SOIG) and in 10 patients with high-pressure primary open-angle glaucoma (POAG) despite maximum tolerated medical therapy. • Methods: Intraocular pressure (TOP) measurements were carried out before and 1, 2 and 3 h after a single drop of apraclonidine. • Results: Patients with SIOG presented with a mean IOP of 30.0 ± 2.8 mmHg, which was reduced to 21.7 ± 2.9 mmHg (P<0.001) after 1 h, to 20.4 ± 2.3 mmHg (P<0.001) after 2 h and to 20.0±2.5 mmHg (P<0.001) after 3 h. In the POAG group, TOP was reduced from 25.9±1.9 mmHg before treatment to 18.9±1.4 mmHg after 1 h (P<0.001), 17.7±1.2 mmHg after 2 h (P<0.001) and 16.9±0.9 mmHg after 3 h (P<0.001). There were no significant changes in blood pressure or pulse rate. • Conclusion: This study confirmed the activity of apraclonidine as an TOP suppressant.